The quality debt of clinical trials: how small operational deviations accumulate into scientific and regulatory risk

Authors

DOI:

https://doi.org/10.18203/2349-3259.ijct20264259

Keywords:

Clinical trials quality, Risk-based quality management, Protocol deviations, Corrective and preventive action, Quality by design, Residual risk

Abstract

Clinical trial quality depends on several interconnected processes that protect participants and support the reliability of study data. Protocol deviations, audit findings and corrective and preventive action (CAPA) records help identify quality concerns. However, the number of recorded findings and their administrative closure status may not fully reflect the residual risk within a clinical trial. This review introduces the concept of quality debt in clinical trials to examine quality vulnerabilities that develop or persist during trial conduct. A conceptual review was undertaken using selected regulatory guidance and scientific publications addressing good clinical practice, quality by design, risk-based monitoring, protocol deviations, protocol complexity and clinical trial quality management. The literature was examined to develop a working definition and identify potential dimensions of the proposed concept. The objective was conceptual development rather than systematic evidence synthesis. Quality debt is proposed as a framework for examining residual quality risk arising from deficiencies that persist, recur, interact or remain inadequately controlled despite corrective actions. Five candidate dimensions were identified: criticality, persistence, recurrence, remediation effectiveness, interaction and residual risk. Together, these dimensions encourage consideration of the underlying quality conditions rather than relying solely on event counts or administrative closure status. Quality debt may offer an additional perspective on how unresolved quality vulnerabilities accumulate during clinical trial conduct. However, the concept remains theoretical, and its dimensions have not been operationally defined or validated. Further research is needed to determine whether it provides meaningful information beyond existing clinical trial quality-management approaches.

References

European Medicines Agency. ICH E8(R1): General considerations for clinical studies. 2021. Available at: https://www.ema.europa.eu/en/ich-e8-general-considerations-clinical-studies. Accessed on 16 September 2026.

European Medicines Agency. ICH E6(R3): Guideline for good clinical practice. 2025. Available at: https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline. Accessed on 16 September 2026.

U.S. Food and Drug Administration (FDA). Oversight of clinical investigations: a risk-based approach to monitoring. 2013. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/over sight-clinical-investigations-risk-based-approach-monitoring. Accessed on 16 September 2026.

U.S. Food and Drug Administration (FDA). A risk-based approach to monitoring of clinical investigations: questions and answers. 2023. Available at: https://www.fda.gov/ regulatory-information/search-fda-guidance-documents/risk-based-approach-monitoring-clinical-investigations-questions-and-answers. Accessed on 16 September 2026.

Mehra M, Kurpanek K, Petrizzo M, Brenner S, McCracken Y, Katz T, et al. The life cycle and management of protocol deviations. Ther Innov Regul Sci. 2014;48(6):762-77.

Willigers BJA, Wiesiolek AE, Potter B, Pszczółkowska A, Kristensson C, Presz V, et al. Development of a protocol complexity tool: a framework designed to stimulate discussion and simplify study design. BMC Med Res Methodol. 2025;25:205.

Bozzetti M, Caruso R, Soncini S, Guberti M. Development of the clinical trial site performance metrics instrument: a study protocol. MethodsX. 2025;14:103165.

Meeker-O'Connell A, Glessner C, Behm M, Mulinde J, Roach N, Sweeney F, et al. Enhancing clinical evidence by proactively building quality into clinical trials. Clin Trials. 2016;13(4):439-44.

Meeker-O'Connell A, Sam LM, Bergamo N, Little JA. TransCelerate's Clinical Quality Management System: from a vision to a conceptual framework. Ther Innov Regul Sci. 2016;50(4):397-413.

TransCelerate. Risk-based monitoring. 2021. Available at: https://www.transceleratebiopharmai nc.com/initiatives/risk-based-monitoring/. Accessed on 16 September 2026.

Clinical Trials Transformation Initiative. Quality by design. Available at: https://ctticlinicaltrials.org/ about/ctti-projects/quality-by-design/. Accessed on 16 September 2026.

Bakobaki JM, Rauchenberger M, Joffe N, McCormack K, Stables S. The potential for central monitoring techniques to replace on-site monitoring. Clin Trials. 2012;9(2):257-64.

Brosteanu O, Houben P, Ihrig K, Ohmann C, Paulus U, Pfistner B, et al. Risk-adapted monitoring is not inferior to extensive on-site monitoring. Clin Trials. 2017;14(6):584-96.

Journot V, Pignon JP, Gaultier C, Daurat V, Bouxin-Métral E, Giraudeau B, et al. Validation of a risk-assessment scale and centralized monitoring. Clin Trials. 2011;8(2):270-8.

Eisenstein EL, Lemons PW, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing costs in phase III cardiovascular clinical trials. Am Heart J. 2005;149(3):482-8.

Getz KA, Campo RA. Trial watch: trends in clinical trial design complexity. Nat Rev Drug Discov. 2017;16(5):307.

Getz KA. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther. 2008;15(5):450-7.

Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin KI. Quantifying the magnitude and cost of collecting extraneous protocol data. Am J Ther. 2015;22(2):117-24.

Parry TJ, Carson-Stevens A, Luff DF, McPherson ME. Clinical trial quality management systems: implementation and evaluation. Drug Inf J. 2010;44(2):171-80.

Rooney JJ, Vanden Heuvel LN. Root cause analysis for beginners. Qual Prog. 2004;37(7):45-53.

Andersen B, Fagerhaug T. Root Cause Analysis: Simplified tools and techniques. 2nd edition. ASQ; 2006.

International Organization for Standardization (ISO). ISO 9001:2015 quality management systems - requirements. 2015. Available at: https://www. iso.org/standard/62085.html. Accessed on 16 September 2026.

Getz KA, Campo RA, Kaitin KI. Variability in protocol design complexity by phase and therapeutic area. Drug Inf J. 2011;45(4):413-20.

Adams A, Adelfio A, Barnes B, Berlien R, Branco D, Coogan A, et al. Risk-based monitoring in clinical trials: 2021 update. Ther Innov Regul Sci. 2023;57(3):529-37.

Morrison BW, Cochran CJ, White JG, Harley J, Kleppinger CF, Liu A, et al. The Clinical Trials Transformation Initiative's Quality by Design project: defining principles to enhance quality in clinical trials. Clin Trials. 2015;12(5):458-66.

Nahm ML, Pieper CF, Cunningham MM. Quantifying data quality for clinical trials using electronic data capture. PLoS One. 2008;3(8):e3049.

Kruchten P, Nord RL, Ozkaya I. Technical debt: from metaphor to theory and practice. IEEE Softw. 2012;29(6):18-21.

Li Z, Avgeriou P, Liang P. A systematic mapping study on technical debt and its management. J Syst Softw. 2015;101:193-220.

Downloads

Published

2026-11-19

How to Cite

Malle, A. B., Pawar, S. D., & Pal, P. S. (2026). The quality debt of clinical trials: how small operational deviations accumulate into scientific and regulatory risk. International Journal of Clinical Trials. https://doi.org/10.18203/2349-3259.ijct20264259

Issue

Section

Review Articles